Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15
Sight Sciences (Nasdaq: SGHT) announced that its management will present at the Morgan Stanley Global Healthcare Conference in New York, NY.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sight Sciences (Nasdaq: SGHT) announced that its management will present at the Morgan Stanley Global Healthcare Conference in New York, NY. The presentation is scheduled for Tuesday, September 15, 2026, at 6:15 a.m. PT / 9:15 a.m. ET. Interested investors can access a live and archived webcast of the fireside chat via the Investors section of the Sight Sciences website.
Details
News Market Reaction – SGHT
On Sep 2, the first trading day after this news, SGHT closed 2.81% above the previous close. Argus tracked a peak move of +2.6% during that session. Our momentum scanner recorded 12 alerts for this stock that day. Relative volume reached 6.9x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
Key Figures
- Presentation Date
- September 15, 2026
- Morgan Stanley Global Healthcare Conference
- Presentation Time
- 6:15 am PT / 9:15 am ET
- Management presentation
Historical Context
-
FDA updated TearCare indications to improve meibomian gland function
-
Revenue growth, improved loss, and raised full-year revenue guidance
-
Aetna recognized OMNI and SION systems as medically necessary
-
FDA cleared OMNI Ultra for canaloplasty followed by trabeculotomy
-
Company scheduled its second-quarter financial results announcement
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
Sight Sciences’ management is scheduled to present on Tuesday, September 15, 2026, at 6:15 am PT / 9:15 am ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the Company’s website at: https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information.
Sight Sciences, TearCare, and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI, SION, and the Sight Sciences logo are trademarks of Sight Sciences registered in the United States, European Union and other territories. TruSync is a trademark of Sight Sciences.
© 2026 Sight Sciences. All rights reserved.
Media contact:
pr@sightsciences.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
investor.relations@sightsciences.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.